CSIMarket
 
Day One Biopharmaceuticals Inc   (NASDAQ: DAWN)
Other Ticker:  
 
 
Price: $12.0500 $-0.46 -3.677%
Day's High: $12.61 Week Perf: -0.17 %
Day's Low: $ 11.94 30 Day Perf: -2.82 %
Volume (M): 773 52 Wk High: $ 18.07
Volume (M$): $ 9,310 52 Wk Avg: $14.22
Open: $12.45 52 Wk Low: $11.13



 Market Capitalization (Millions $) 1,168
 Shares Outstanding (Millions) 97
 Employees 49
 Revenues (TTM) (Millions $) 102
 Net Income (TTM) (Millions $) -117
 Cash Flow (TTM) (Millions $) 182
 Capital Exp. (TTM) (Millions $) 18

Day One Biopharmaceuticals Inc
Day One Biopharmaceuticals is a privately held, clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company was founded in 2018 by Jeremy Bender, M.D., Ph.D., a former partner at Deerfield Management, and Josh Resnick, CEO of the oncology company, Outpost Medicine. Day One Biopharmaceuticalse primary focus is on developing precision medicines for patients with cancer and autoimmune disorders. The company received $60 million in funding in a Series A round led by ARCH Venture Partners and includes Pfizer Ventures, Lux Capital, GV, and Alexandria Venture Investments.

One of the main reasons for the company's founding is to bring a more personalized approach to cancer treatment. Day One Biopharmaceuticals concentrates on identifying targets that are highly expressed in specific subtypes of cancer and developing highly selective drugs that zero in on those targets. This is done using its proprietary platform, which combines single-cell sequencing, proteomics, and artificial intelligence (AI) techniques to identify and focus on targets that are present only on cancer cells, leaving healthy cells unharmed.

Another area of focus for Day One Biopharmaceuticals is autoimmune diseases since the platform it uses to identify drug targets could also find targets on cells that are driving autoimmune disorders. The company's pipeline starts with two oncology programs targeting the RAS and Myc cancer pathways, both of which are known for their complexity and elusiveness in therapeutic targeting. Day Onees scientific approach is expected to be highly effective, given the complexity of these developmental pathways. Other programs it is working on target novel metabolic pathways in cancer cells as well as cytokine targets and immune cells for autoimmune disease.

In summary, Day One Biopharmaceuticals is an innovative, privately held clinical-stage biopharmaceutical company with a mission to develop highly selective drugs using its proprietary AI-based platform for cancer and autoimmune diseases. With significant funding from a range of investors, the company is well-positioned to make progress in its pipeline of novel therapies.


   Company Address: 2000 Sierra Point Parkway Brisbane 94005 CA
   Company Phone Number: 484-0899   Stock Exchange / Ticker: NASDAQ DAWN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALNY        0.6% 
BMRN        2.39% 
JAZZ   -1.38%    
TEVA   -3%    
VRTX   -3%    
VTRS   -2.08%    
• View Complete Report
   



Management Announcement

Day One Biopharmaceuticals Secures Oversubscribed $175 Million Private Placement, While Maintaining Highest ROI Ranking in Healthcare Sector

Published Tue, Jul 30 2024 11:00 AM UTC


BRISBANE, Calif., July 30, 2024 - Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) has made significant strides in securing funding for its mission of developing and commercializing targeted therapies for individuals with life-threatening diseases. The commercial-stage biopharmaceutical company recently announced an oversubscribed private placement of its securities, rai...

Clinical Study

Day One Acquires Exclusive License for Revolutionary ADC, MTX-13, Targeting PTK7 in Solid Tumors, Advancing Cancer Tr...

Published Tue, Jun 18 2024 12:30 PM UTC

Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric CancersDay One, a leading biotechnology company focused on developing innovative therapies for cancer and rare diseases, has recently announced the expansion of its pipeline with the potential first-in-class clinical-stage...

Financing Agreement

Day One Biopharmaceuticals Achieves Record High Leverage Ratio Amidst $108 Million Priority Review Voucher Sale

Published Thu, May 30 2024 12:30 PM UTC



On May 30, 2024, Day One Biopharmaceuticals, a leading biopharmaceutical company focused on developing and commercializing targeted therapies, made a significant announcement. The company successfully sold its Priority Review Voucher (PRV) for a staggering $108 million to an undisclosed buyer. This exciting development comes on the heels of the U.S. Food and Drug A...

Clinical Study

FDA Fast-Tracks Approval for OJEMDA, Day One's Novel Treatment for Leading Childhood Brain Tumor, MARKS Major Leap Forward in Pediatric Oncology

Published Tue, Apr 23 2024 7:56 PM UTC

This latest regulatory green light marks just the latest affirmation of Day One s ongoing commitment to revolutionizing the treatment paradigm in pediatric oncology. With gliomas accounting for nearly half of all central nervous system tumors in children, the approval of OJEMDA is set to herald a new era of hope for pediatric patients and their families grappling with this c...

Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc. Shocks Stock Market with Surprising Third Quarter Results

The stock market has been buzzing with speculation and anticipation as industry observers continue to analyze the third quarter earnings of the Major Pharmaceutical Preparations industry. In their scrutiny, one company that has caught their attention is Day One Biopharmaceuticals Inc.
The latest financial reporting period, covering July to September 2023, saw Day One Biopharmaceuticals Inc report an operating deficit of -$51.438 million. While the company has yet to disclose any top-line figures, investors remain optimistic about the future revenue streams that may emerge in the near future.







Day One Biopharmaceuticals Inc's Segments





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com